July 13, 2026 Uncategorized BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism Read More
July 9, 2026 Uncategorized BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee Read More
July 6, 2026 Uncategorized BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1 Read More
